The Effect of GnRH Agonist Administered in the Luteal Phase on ART Cycle Outcomes
Infertility
About this trial
This is an interventional treatment trial for Infertility focused on measuring Luteal phase support,GnRH agonist,ART cycles
Eligibility Criteria
Inclusion Criteria:
- Couples undergoing ART with their own gametes.
- Couples having at least one good embryo available for transfer.
- Normoresponder
- Infertility etiology is unexplained
- ovulation triggered by intramuscular injection of 10000 IU of HCG
Exclusion Criteria:
Patients older than 38 years old
- High and poor responder patients
Sites / Locations
- Zekai Tahir Burak Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Active Comparator
Experimental
Active Comparator
Experimental
LongGnRH agonist protocol(controlgroup)
Long protocol-leuprolide acetate
GnRHantagonist protocol(control group)
antagonist protocol-leuprolide acetate
Long GnRH agonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
Long GnRH agonist protocol Luteal Phase Support: Vaginal progesterone+oral estradiol valerate subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer
GnRH antagonist protocol ( control group) Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate
GnRH antagonist protocol Luteal Phase Support: Vaginal progesterone + 4mg oral estradiol valerate + subcutaneous 0.5mg leuprolide acetate fifth and tenth day after embryo transfer